Because the Brca1-deficient mammary tumor latency spans 4–12 months with mice developing multiple tumors with different growth kinetics, we initially sought to study this combination using a simpler tumor model in which the mice acquired tumors at relatively the same time, and the duration of therapy was relatively short. This evidence concerns the gene BRCA1 and neoplasm.